Crescendo Biologics out-licenses 'Humabody' asset to Zai Lab

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Meletios Verras)
(Image: Getty/Meletios Verras)
Zai Lab and Crescendo Biologics have signed a licensing agreement under which Zai Lab will develop protein therapeutics for inflammatory indications.

The Shanghai-based biopharmaceutical company Zai Lab Limited and Crescendo Biologics Ltd,​ a multi-functional biologics developer based in the UK, have announced an exclusive, worldwide licensing agreement.

Under the agreement, Zai Lab will develop, commercialize, and manufacture a topical antibody VH domain therapeutic for potential application in inflammatory indications. 

According to the Crescendo, this is the first "Humabody" asset to be out-licensed. The company describes its Humabody products as a "novel class of small, robust and potent protein therapeutics based on fully human VH domain building blocks(Humabody VH)."

The name of the asset covered by the agreement was not disclosed.

Zai Lab – which has made an undisclosed upfront cash payment to Crescendo Biologics – also will be responsible for conducting regulatory filings, clinical studies, and commercialization activities. It expects to file an investigational new drug application (IND) for clinical studies in psoriasis in 2019.

Biologics-based therapies are increasingly effective in psoriasis and other skin conditions, but are often associated with treatment-limiting immunosuppressive side effects,”​ said Harald Reinhart, MD, chief medical officer, autoimmune and infectious diseases at Zai Lab in a press release.

“We see a clear benefit with topically administered dermatologic preparations which offers strong clinical efficacy and potentially safer for chronic administration,”​ he added.

Backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital, Astellas, and EMBL Ventures, Crescendo is pursuing novel Humabody-based product opportunities via in-house development and strategic partnerships, according to the company.

Crescendo in April completed a $70m (€57m) Series B financing round. The funds will be used to advance the development of its lead program, CB307, which stimulates local activation of tumor-specific T-cells.

Related news

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Related suppliers

Follow us


View more